Diabetes is a condition that interferes with blood sugar levels in people whose bodies don't produce the right amount of insulin — a hormone made in the pancreas. Blood sugar that’s too high ...

Please provide your email address to receive an email when new articles are posted on . Change in HbA1c and hypoglycemia rates were similar between once-weekly basal insulin and once-daily insulin ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Once-weekly insulin efsitora alfa was noninferior to ...

Medical device software company Voluntis has received an updated FDA clearance (as well as an updated CE mark) for its Insulia app, a "digital companion" app for people with Type 2 diabetes. Insulia ...

Dexcom Smart Basal is FDA cleared and now the first and only CGM-integrated basal insulin dosing optimizer for adults aged 18 and older with Type 2 diabetes who are using long-acting insulin. Dexcom ...

SAN DIEGO – The investigational once-weekly insulin icodec provided superior glucose control compared with the once-daily basal insulins degludec and glargine in type 2 diabetes, results from two new ...

On the heels of an FDA rejection for its chief rival Novo Nordisk, Eli Lilly is gaining ground in the race to bring a once-weekly insulin to the U.S. Early Thursday, Lilly unveiled positive top-line ...

HAMBURG, Germany -- Adding weekly tirzepatide (Mounjaro) to basal insulin reduced HbA1c in patients with poorly controlled type 2 diabetes compared with adding three-times-daily insulin lispro, the ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

Hypoglycemia after basal insulin initiation is associated with high clinical and economic burden that precedes insulin initiation and persists during 1 to 2 years of follow-up. Objectives: To assess ...

BAGSVAERD, Denmark, Sept. 22, 2020 /PRNewswire/ -- Today, Novo Nordisk announced results from three phase 2 clinical trials for insulin icodec, an investigational once-weekly basal insulin analogue, ...